Group42 (G42) Healthcare, a leading health-tech company, and Seegene, a South Korean biotechnology company specialized in molecular diagnostics, have signed a Memorandum of Understanding (MoU) to offer fully equipped mobile diagnostics and testing laboratories across the Middle East and North Africa (MENA) region.
The collaboration will offer the innovative Seegene Mobile Station, a laboratory-on-wheels facility providing optimized molecular diagnosis and tests at any location to safeguard the health of communities with the WHO guidelines of BioSafety Level-2.
The mobile station has all key diagnostic testing equipment like RT-PCR reagents, consumables, IT solutions, and technical support which can be transported by ship or land. It enables users to conduct up to 2,000 tests per day, including for 225 pathogens.
The services will be available across MENA, including the UAE, Algeria, Morocco, Tunisia, Libya, Egypt, Sudan, Palestine, Jordan, Syria, Iraq, Iran, Pakistan, Lebanon, Kuwait, Qatar, Oman, Saudi Arabia, Bahrain, and Yemen.
Mr. Ashish Koshy, CEO of G42 Healthcare, said, “Our commitment is to uphold patient health and reinforce our credentials as a transformation enabler in healthcare for the good of all humanity. We are proud to enter into a collaboration with Seegene which offers equitable access to healthcare anywhere in the Pan-Arab region”.
“The Mobile Station will significantly contribute to mitigation efforts as it will help governments to control areas where epidemics spread easily and to place the laboratory near crowded places, such as community events,” said Mr. James Park, Seegene Executive Director.
G42 Healthcare, located in Abu Dhabi, is a health tech business that uses artificial intelligence, scientific research, and technology in genomics, digital health, diagnostics, and clinical trials to improve the healthcare sector in the United Arab Emirates and overseas.